ZYDUS LIFESCIENCES
Quarterly Results Analysis [Dec2024]
ZYDUS LIFESCIENCES Quarterly Results
Consolidated | Dec2024 UnAudited |
Sep2024 UnAudited |
Jun2024 UnAudited |
Mar2024 UnAudited |
Dec2023 UnAudited |
Sep2023 UnAudited |
Jun2023 UnAudited |
Mar2023 Audited |
---|---|---|---|---|---|---|---|---|
Revenues | ₹5,269 Cr | ₹5,237 Cr | ₹6,208 Cr | ₹5,534 Cr | ₹4,505 Cr | ₹4,369 Cr | ₹5,140 Cr | ₹5,011 Cr |
Expenses | ₹3,882 Cr | ₹3,821 Cr | ₹4,124 Cr | ₹3,909 Cr | ₹3,403 Cr | ₹3,305 Cr | ₹3,634 Cr | ₹3,755 Cr |
Operating Income | ₹1,388 Cr | ₹1,416 Cr | ₹2,084 Cr | ₹1,625 Cr | ₹1,102 Cr | ₹1,064 Cr | ₹1,505 Cr | ₹1,256 Cr |
Other Income | ₹58 Cr | ₹114 Cr | ₹63 Cr | ₹162 Cr | ₹38 Cr | ₹136 Cr | ₹36 Cr | ₹38 Cr |
Interest | ₹32 Cr | ₹25 Cr | ₹32 Cr | ₹35 Cr | ₹20 Cr | ₹9 Cr | ₹18 Cr | ₹28 Cr |
Depreciation | ₹229 Cr | ₹234 Cr | ₹215 Cr | ₹205 Cr | ₹195 Cr | ₹184 Cr | ₹180 Cr | ₹179 Cr |
Profit Before Tax | ₹1,184 Cr | ₹1,271 Cr | ₹1,900 Cr | ₹1,547 Cr | ₹926 Cr | ₹1,007 Cr | ₹1,329 Cr | ₹486 Cr |
Profit After Tax | ₹1,005 Cr | ₹898 Cr | ₹1,464 Cr | ₹1,226 Cr | ₹712 Cr | ₹781 Cr | ₹1,113 Cr | ₹349 Cr |
EPS | ₹10.17 | ₹9.06 | ₹14.11 | ₹11.75 | ₹7.80 | ₹7.91 | ₹10.74 | ₹2.93 |
Industry Peers & Returns | 1W | 1M | 1Y |
ZYDUS LIFESCIENCES | 3.2% | -1% | 27.4% |
SUN PHARMACEUTICAL INDUSTRIES | 0.6% | -2.1% | 16.5% |
CIPLA | 3.6% | 0.2% | 2.3% |
DR REDDYS LABORATORIES | 3% | -8.4% | 0% |
DIVIS LABORATORIES | 4.3% | 6.5% | 63.9% |
MANKIND PHARMA | -2.5% | -8% | 16.5% |
TORRENT PHARMACEUTICALS | 2.9% | -0.5% | 19.4% |
LUPIN | 8.2% | 0.4% | 37% |
AUROBINDO PHARMA | 5.8% | -0.7% | 19.5% |
ZYDUS LIFESCIENCES Quarterly Revenues
Revenues | |
---|---|
Q-o-Q | 0.61 % |
Y-o-Y | 16.96 % |
Quarters | Revenues | % Change | |
---|---|---|---|
Dec2024 | ₹5,269 Cr | 0.61 | |
Sep2024 | ₹5,237 Cr | -15.63 | |
Jun2024 | ₹6,208 Cr | 12.17 | |
Mar2024 | ₹5,534 Cr | 22.83 | |
Dec2023 | ₹4,505 Cr | 3.12 | |
Sep2023 | ₹4,369 Cr | -15.00 | |
Jun2023 | ₹5,140 Cr | 2.57 | |
Mar2023 | ₹5,011 Cr | - |
ZYDUS LIFESCIENCES Quarterly Operating Profit
Operating Profit | |
---|---|
Q-o-Q | -2.01 % |
Y-o-Y | 25.87 % |
Quarters | Operating Profit | % Change | |
---|---|---|---|
Dec2024 | ₹1,388 Cr | -2.01 | |
Sep2024 | ₹1,416 Cr | -32.05 | |
Jun2024 | ₹2,084 Cr | 28.23 | |
Mar2024 | ₹1,625 Cr | 47.42 | |
Dec2023 | ₹1,102 Cr | 3.62 | |
Sep2023 | ₹1,064 Cr | -29.32 | |
Jun2023 | ₹1,505 Cr | 19.89 | |
Mar2023 | ₹1,256 Cr | - |
Operating Margins | |
---|---|
Q-o-Q | -2.63 % |
Y-o-Y | 7.60 % |
Quarters | Operating Margin% | % Change | |
---|---|---|---|
Dec2024 | 26.33% | -2.63 | |
Sep2024 | 27.04% | -19.45 | |
Jun2024 | 33.57% | 14.30 | |
Mar2024 | 29.37% | 20.02 | |
Dec2023 | 24.47% | 0.49 | |
Sep2023 | 24.35% | -16.87 | |
Jun2023 | 29.29% | 16.88 | |
Mar2023 | 25.06% | - |
ZYDUS LIFESCIENCES Quarterly Profit After Tax
Profit After Tax(PAT) | |
---|---|
Q-o-Q | 11.90 % |
Y-o-Y | 41.15 % |
Quarters | Profit After Tax | % Change | |
---|---|---|---|
Dec2024 | ₹1,005 Cr | 11.90 | |
Sep2024 | ₹898 Cr | -38.66 | |
Jun2024 | ₹1,464 Cr | 19.40 | |
Mar2024 | ₹1,226 Cr | 72.24 | |
Dec2023 | ₹712 Cr | -8.85 | |
Sep2023 | ₹781 Cr | -29.85 | |
Jun2023 | ₹1,113 Cr | 219.31 | |
Mar2023 | ₹349 Cr | - |
PAT Margins | |
---|---|
Q-o-Q | 11.26 % |
Y-o-Y | 20.70 % |
Quarters | PAT Margin(%) | % Change | |
---|---|---|---|
Dec2024 | 19.07 % | 11.26 | |
Sep2024 | 17.14 % | -27.31 | |
Jun2024 | 23.58 % | 6.46 | |
Mar2024 | 22.15 % | 40.19 | |
Dec2023 | 15.8 % | -11.58 | |
Sep2023 | 17.87 % | -17.50 | |
Jun2023 | 21.66 % | 211.21 | |
Mar2023 | 6.96 % | - |
ZYDUS LIFESCIENCES Quarterly Earnings Per Share (EPS)
EPS | |
---|---|
Q-o-Q | 12.25 % |
Y-o-Y | 30.38 % |
Quarters | EPS | % Change | |
---|---|---|---|
Dec2024 | ₹10.17 | 12.25 | |
Sep2024 | ₹9.06 | -35.79 | |
Jun2024 | ₹14.11 | 20.09 | |
Mar2024 | ₹11.75 | 50.64 | |
Dec2023 | ₹7.8 | -1.39 | |
Sep2023 | ₹7.91 | -26.35 | |
Jun2023 | ₹10.74 | 266.55 | |
Mar2023 | ₹2.93 | - |
You may also like the below Video Courses
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs MANKIND PHARMA LTD